DCT

1:26-cv-00688

AbbVie Inc v. Annora Pharma Pvt Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00688, D. Del., 06/11/2026
  • Venue Allegations: Venue is alleged to be proper as Defendant Hetero USA, Inc. is a Delaware corporation, and Defendant Annora Pharma Private Limited is an alien corporation that may be sued in any judicial district. The complaint further alleges that Defendants have continuous and systematic contacts with Delaware and intend to sell the accused product in the state.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's RINVOQ® LQ oral solution constitutes an act of infringement of two U.S. patents.
  • Technical Context: The technology relates to Janus kinase (JAK) inhibitors, specifically the compound upadacitinib, used for treating immune-mediated diseases such as psoriatic arthritis and juvenile idiopathic arthritis.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendants' submission of ANDA No. 221524 and a Paragraph IV certification notice letter to AbbVie. The complaint notes a dispute between the parties regarding the terms of confidential access to the ANDA, with AbbVie alleging the terms offered by Annora are unreasonably restrictive.

Case Timeline

Date Event
2015-10-16 '584 Patent Priority Date
2016-06-20 '689 Patent Priority Date
2021-11-30 '584 Patent Issue Date
2025-07-22 '689 Patent Issue Date
2026-04-28 Annora sends Notice Letter to AbbVie
2026-06-11 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,186,584 - "Processes for the Preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof"

  • Patent Identification: U.S. Patent No. 11,186,584, issued November 30, 2021.

The Invention Explained

  • Problem Addressed: The patent's background section describes challenges in the commercial-scale preparation of the active pharmaceutical ingredient (API) upadacitinib ("Compound 1") '584 Patent, col. 2:6-10 These challenges include finding a solid-state form with acceptable physical properties (e.g., chemical and thermal stability, solubility, hygroscopicity) and developing manufacturing processes that avoid particularly hazardous reagents like diazomethane '584 Patent, col. 2:10-28
  • The Patented Solution: The patent discloses processes for preparing Compound 1 and various solid-state forms thereof, including crystalline hydrates, anhydrates, and salts, which are asserted to have an acceptable balance of properties for pharmaceutical development '584 Patent, abstract '584 Patent, col. 2:18-23 The invention also describes specific pharmaceutical compositions, such as extended-release tablets, that utilize these solid-state forms to achieve desired release profiles '584 Patent, col. 2:31-50 Figure 1A illustrates a detailed manufacturing process flow for creating an amorphous freebase form of the API via a hydrate intermediate '584 Patent, FIG. 1A
  • Technical Importance: The development of stable, manufacturable solid-state forms and reliable formulations is a critical step in transforming a promising chemical compound into a viable and commercially successful oral drug product.

Key Claims at a Glance

  • The complaint does not identify specific claims asserted against Defendants Compl. ¶46 For the purpose of this analysis, representative independent claim 16 is examined.
  • Independent Claim 16 of the '584 Patent recites:
    • A pharmaceutical composition comprising
    • a crystalline hydrate of Compound 1
    • and a pharmaceutically acceptable carrier,
    • wherein the crystalline hydrate is a hemihydrate.

U.S. Patent No. 12,365,689 - "Processes for the Preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof"

  • Patent Identification: U.S. Patent No. 12,365,689, issued July 22, 2025.

The Invention Explained

  • Problem Addressed: The patent's background section notes that while upadacitinib is approved for use in adults, its pharmacokinetics, safety, and efficacy had not been evaluated in pediatric patients, particularly those under 12 years of age or weighing less than 40 kg '689 Patent, col. 2:19-24 The patent highlights the need for safe and effective weight-based dosing regimens for this population '689 Patent, col. 2:21-24
  • The Patented Solution: The patent claims methods for treating juvenile idiopathic arthritis (JIA) in pediatric patients by administering upadacitinib using a stable liquid formulation or solid dosage form, with the dose determined by the patient's body weight category '689 Patent, abstract '689 Patent, col. 9:1-15 The specification describes the clinical study design used to establish these dosing regimens, a schematic of which is provided in Figure 10 '689 Patent, FIG. 10
  • Technical Importance: Establishing safe and effective weight-based dosing regimens for pediatric patients is essential for extending the therapeutic use of a drug to children, who may metabolize drugs differently and require doses adjusted for body size.

Key Claims at a Glance

  • The complaint does not identify specific claims asserted against Defendants Compl. ¶68 For the purpose of this analysis, representative independent claim 4 is examined.
  • Independent Claim 4 of the '689 Patent recites:
    • A method for treating polyarticular course juvenile idiopathic arthritis (pcJIA) in a pediatric patient... comprising administering a therapeutically effective amount of upadacitinib... wherein:
    • if the pediatric patient has a body weight in a range from about 10 kg to less than about 20 kg, administering upadacitinib twice daily as an oral pharmaceutical solution at a dose of 3 mg each (3 mg BID);
    • if the pediatric patient has a body weight in a range from about 20 kg to less than about 30 kg, administering upadacitinib twice daily as an oral pharmaceutical solution at a dose of 4 mg each (4 mg BID); and
    • if the pediatric patient has a body weight of about 30 kg or greater, administering upadacitinib twice daily as an oral pharmaceutical solution at a dose of 6 mg each (6 mg BID), or administering upadacitinib once daily as a tablet at a dose of 15 mg (15 mg QD).

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Annora's ANDA Product," identified as ANDA No. 221524, which seeks FDA approval to market a generic version of AbbVie's RINVOQ® LQ product Compl. ¶1 Compl. ¶15

Functionality and Market Context

The accused product is a 1 mg/mL oral solution of upadacitinib, the active ingredient in RINVOQ® LQ Compl. ¶1 Compl. ¶7 RINVOQ® LQ is described as a treatment for pediatric patients with active psoriatic arthritis and active polyarticular juvenile idiopathic arthritis Compl. ¶2 The complaint alleges that upon approval, Annora intends to commercially manufacture, market, and sell this generic product throughout the United States Compl. ¶17

IV. Analysis of Infringement Allegations

The complaint alleges infringement of one or more claims of the '584 Patent and '689 Patent but does not identify which specific claims are asserted or provide a claim-by-claim analysis of infringement Compl. ¶¶46, 68 As such, the complaint does not provide sufficient detail for a tabular claim chart analysis. The following points of contention are based on the representative claims selected in Section II.

  • Identified Points of Contention ('584 Patent):
    • Evidentiary Question: The primary dispute regarding infringement of a composition claim like claim 16 will be factual and evidentiary. A key question will be whether Annora's process for manufacturing its API results in the specific "crystalline hydrate... [which] is a hemihydrate" claimed in the patent. AbbVie currently lacks access to the confidential portions of Annora's ANDA that would contain this information Compl. ¶40
  • Identified Points of Contention ('689 Patent):
    • Induced Infringement Question: Infringement of a method-of-treatment claim like claim 4 would occur by inducement. The central question will be whether the proposed product label for Annora's ANDA Product will instruct or encourage physicians to prescribe the oral solution to pediatric patients for pcJIA according to the weight-based dosing regimens recited in claim 4. This would require analysis of the proposed label submitted with the ANDA.
    • Scope Question: The claim recites dosing based on body weight ranges such as "about 10 kg to less than about 20 kg." The construction of the term "about" may become a point of contention, raising the question of how much deviation from the specified numerical weight boundaries is permissible while still falling within the claim's scope.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

  • For the '584 Patent:

    • The Term: "crystalline hydrate...wherein the crystalline hydrate is a hemihydrate"
    • Context and Importance: This term is the core of representative composition claim 16. The infringement analysis will depend entirely on whether the API used by Annora meets this specific structural definition. Practitioners may focus on this term because the case could be resolved by determining the exact solid-state form of the API disclosed in Annora's ANDA.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification discusses hydrates of Compound 1 generally, which could suggest the term should not be limited to a single specific polymorph unless explicitly claimed as such '584 Patent, col. 16:65-67
      • Evidence for a Narrower Interpretation: The patent provides detailed characterization data for a specific hemihydrate form, designated "Freebase Hydrate Form C," including its PXRD pattern, thermal analysis, and single-crystal data '584 Patent, FIGS. 3C, 4E, 5C '584 Patent, Table 16-C A party may argue that the term should be construed as being limited to the specifically disclosed and characterized hemihydrate form.

  • For the '689 Patent:

    • The Term: "about" (as in "about 10 kg," "about 30 kg")
    • Context and Importance: This term provides flexibility to the numerical body weight ranges that define the dosing regimens in method claim 4. The extent of this flexibility will be critical in determining whether prescribing instructions on a generic label induce infringement, especially for patients near the boundaries of the weight categories.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The term "about" is used throughout the patent's claims and specification without a precise numerical definition, which may suggest it should be given its ordinary meaning of "approximately" as understood by a person of ordinary skill in the art of pediatric dosing '689 Patent, claim 4
      • Evidence for a Narrower Interpretation: The patent describes clinical studies with specific cohort definitions and presents pharmacokinetic data corresponding to those cohorts '689 Patent, FIG. 10 '689 Patent, Table 21 A party might argue that "about" should be construed narrowly to encompass only minor variations from the stated weights, consistent with the precision of the underlying clinical data.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Annora will actively induce infringement of the patents-in-suit Compl. ¶¶41, 71 For the '689 Patent, the infringement theory would be entirely based on inducement, as the claims cover a method of treatment that would be performed by physicians and patients.
  • Willful Infringement: The complaint alleges that Annora has "actual and constructive notice" of the patents-in-suit, in part because they are listed in the FDA's Orange Book for RINVOQ® LQ Compl. ¶¶32-33 Compl. ¶¶50, 72 This alleged knowledge of the patents prior to the infringing activity of filing the ANDA may support a claim for willful infringement.

VII. Analyst's Conclusion: Key Questions for the Case

  1. An Evidentiary and Definitional Question: A central issue for the '584 Patent will be whether the upadacitinib API used to manufacture Annora's ANDA product is, or is made from, a "crystalline...hemihydrate." The resolution will depend on the contents of Annora's confidential ANDA filing and the court's construction of that claim term.
  2. A Label-Driven Inducement Question: For the '689 Patent, the key question is whether the proposed product label for Annora's generic oral solution will instruct or encourage physicians to prescribe it to pediatric patients for pcJIA using the specific weight-based dosing regimens claimed in the patent, which would be the basis for a claim of induced infringement.
  3. A Procedural Question: The complaint details a dispute over AbbVie's access to Annora's ANDA filing Compl. ¶¶38-40 How the court resolves this discovery dispute could significantly impact the early trajectory of the case, as access to the ANDA is necessary for AbbVie to develop its specific infringement contentions.
Loading Complaint